Related references
Note: Only part of the references are listed.Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
Yoon-Koo Kang et al.
GASTRIC CANCER (2022)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
Sandra J. Casak et al.
CLINICAL CANCER RESEARCH (2021)
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Ming Lei et al.
CLINICAL CANCER RESEARCH (2021)
SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors
Yoshiaki Nakamura et al.
CANCER SCIENCE (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Li-Tzong Chen et al.
GASTRIC CANCER (2020)
Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
Richard K. Yang et al.
Oncotarget (2020)
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >= 10: a decision centered on empowering patients and their physicians
V. Subbiah et al.
ANNALS OF ONCOLOGY (2020)
Gain-of-function mutant p53 in cancer progression and therapy
Cen Zhang et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2020)
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Yoshiaki Nakamura et al.
NATURE MEDICINE (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Yang Liu et al.
CANCER CELL (2018)
Why are there hotspot mutations in the TP53 gene in human cancers?
Evan H. Baugh et al.
CELL DEATH AND DIFFERENTIATION (2018)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Putting p53 in Context
Edward R. Kastenhuber et al.
CELL (2017)
Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project
Bo Hwa Sohn et al.
CLINICAL CANCER RESEARCH (2017)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Bernard Leroy et al.
HUMAN MUTATION (2014)
The Origins and Evolution of the p53 Family of Genes
Vladimir A. Belyi et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
The Difference in p53 Mutations between Cancers of the Upper and Lower Gastrointestinal Tract
Eiji Oki et al.
DIGESTION (2009)
The first 30 years of p53: growing ever more complex
Arnold J. Levine et al.
NATURE REVIEWS CANCER (2009)
When mutants gain new powers: news from the mutant p53 field
Ran Brosh et al.
NATURE REVIEWS CANCER (2009)
p53 Gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis:: Results in Japan and comparisons with other countries
Akinori Egashira et al.
CANCER SCIENCE (2007)
Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium
Yuko Matsumoto et al.
NATURE MEDICINE (2007)
Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand
AR Ramiro et al.
NATURE IMMUNOLOGY (2003)
AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts
K Yoshikawa et al.
SCIENCE (2002)
Share Paper
